Itolizumab is a monoclonal antibody used to treat Psoriasis.
Biocon first developed the Itolizumab back in 2013 and has since then granted Equillium rights to develop and commercialize it in the US and Canadian market.
Seeing the success it garnered with its partnership with Equillium, Biocon has recently granted to include the Australian and the New Zealand markets in its licensing agreement.
Mr. Siddharth Mittal, CEO of Biocon has quoted that “As an innovation-led organization, we are committed to bring novel therapeutics to the market to address unmet patient needs across the world.”
As Biocon looks forward to its continued partnership with Equillium in developing treatments for severe autoimmune and inflammatory disorders.